CRISPR Therapeutics
CRSP
CRSP
442 hedge funds and large institutions have $5.19B invested in CRISPR Therapeutics in 2021 Q1 according to their latest regulatory filings, with 107 funds opening new positions, 175 increasing their positions, 95 reducing their positions, and 71 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
9.32% less ownership
Funds ownership: 66.31% → 56.99% (-9.3%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
28% less capital invested
Capital invested by funds: $7.23B → $5.19B (-$2.04B)
Holders
442
Holding in Top 10
5
Calls
$360M
Puts
$396M
Top Buyers
| 1 | +$104M | |
| 2 | +$81.4M | |
| 3 | +$37.7M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$34.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$25.5M |
Top Sellers
| 1 | -$312M | |
| 2 | -$259M | |
| 3 | -$181M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$58M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$47.1M |